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Abstract 23 
Candida albicans metabolic activity in the presence and absence of acetylcholine was measured 24 
using phenotypic microarray analysis. Acetylcholine inhibited C. albicans biofilm formation by 25 
slowing metabolism independent of biofilm forming capabilities. Phenotypic microarray analysis can 26 
therefore be used for screening compound libraries for novel anti-fungal drugs and measuring 27 
antifungal resistance. 28 
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Main Body 43 
Phenotypic microarray (PM) technology has been applied to the field of drug discovery to gain a 44 
better understanding of a compounds efficacy on specific cell types (2, 3); and can be used to 45 
determine the metabolic fingerprint of microbes exposed to drugs (2). Metabolic fingerprinting 46 
provides information on the metabolic pathways employed by a microbe in the presence of 47 
exogenous compounds (2, 3). PM technology has improved knowledge of bacterial growth 48 
inhibitors, strain phenotypes, phenotypes of pathway mutations, drug targets and sensitivity to 49 
chemicals (1, 4, 7, 14, 15). To date, however, no study has applied PM analysis to investigate the 50 
real-time effects of exogenous compounds on the growth characteristics of clinical fungal isolates. 51 
Acetylcholine (ACh) has been demonstrated to modulate host inflammatory responses to infection 52 
and has been shown to inhibit biofilm formation by a C. albicans laboratory type strain (SC5314), 53 
both in vitro and in vivo (8). In this study, we utilised PM technology to investigate the effect of ACh 54 
on 92 clinically relevant bloodstream isolates of C. albicans; collected as part of a candidaemia 55 
epidemiology surveillance study (9, 11). In addition, as high biofilm forming (HBF) strains were found 56 
to correlate with patient mortality (9), we aimed to investigate whether biofilm-forming strains 57 
exhibited differences in susceptibility to ACh.  58 
Bloodstream isolates of C. albicans were sub-cultured, propagated in yeast peptone dextrose, and 59 
metabolic activity monitored by PM analysis during growth in RPMI ± 25 mg/ml ACh, as previously 60 
described (8). The OmniLog reader (Biolog, Hayward, USA) was used to photograph the plates every 61 
15 min to measure dye conversion and the pixel intensity in each well converted to a signal value 62 
reflecting cell metabolic output.  The following information was gathered from the four parameter 63 
logistic fit of average metabolic measurements for each C. albicans isolates (+/- ACh) at each time 64 
point (Mt); the maximum and minimum metabolic values (Mmax and Mmin), the maximum growth rate 65 
(µmax), the lag time (h), the time at the inflection point (ti) and the time taken to reach the half 66 
maximum metabolic rate (µmax) as shown below and in FIG 1 (5):  67 
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Lag time (h) = ti - 1/µmax  x ln((Mmax + Mmax . exp (µmax . ti))/( Mmax + Mmin . exp (µmax . ti)) -1) 68 
Maximum metabolic rates (µmax) were derived from the equation above as follows: 69 
(Mt) = Mmin + (Mmax-Mmin)/1+exp[-µmax (t - ti)] 70 
When M min = 0,  µmax  = [-ln (Mmax-Mt -1)]/(t - ti) 71 
The time to reach half max absorbance (t0.5)  = time (h) that 0.699.Log(Mmax) is reached. 72 
Natural log (Ln) transformations of data were performed where necessary.  Paired sample t-tests 73 
and Bonferroni correction were used to test for significant differences in metabolic characteristics 74 
between untreated and ACh treated C. albicans bloodstream isolates. To determine the relationship 75 
between biofilm formation and ACh sensitivity; C. albicans isolates were split into quartiles based on 76 
biofilm forming ability, as determined previously by crystal violet biomass staining and Syto 9 77 
fluorescence (9). Isolates within the first quartile (Q1; n=19) were classed as low biofilm formers 78 
(LBFs) and isolates above the third quartile (Q3; n=22) were classed as HBFs. Statistical analysis was 79 
performed by ANOVA with a Tukey post-test. 80 
In the presence of ACh, the metabolic activity of 92 C. albicans bloodstream isolates demonstrated 81 
that ACh prolonged the lag phase (p<0.0001), lengthened t0.5 (p<0.001), slowed down the rate of 82 
change in metabolic activity (indicated by a reduction of the gradient [p<0.0001]) and reduced µmax 83 
(p<0.0001) (FIG 2). In addition, ACh also reduced the peak level of metabolic activity (p<0.0001) and 84 
the area under the curve (AUC [p<0.0001]).  85 
In the absence of ACh, ANOVA analysis revealed that there was no significant difference in the lag 86 
phase, the t0.5, the gradient, and the µmax between HBF and LBF isolates. However, a significant 87 
difference was observed for the AUC (p<0.001) (data not shown). In the presence of ACh, the 88 
prolonged lag phase, the increased t0.5, the reduction in peak metabolic activity and reduced AUC 89 
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were all significantly lower (all p<0.001); but comparable for both HBF and LBF isolates (data not 90 
shown).  91 
Collectively, PM analysis indicates that C. albicans ACh susceptibility appears independent of biofilm 92 
forming ability. Therefore, the data suggests that ACh inhibits biofilm formation, principally by 93 
reducing yeast metabolism. Furthermore, the data shows that this phenomenon in not restricted to 94 
laboratory strains based on the observations with a panel of clinically relevant strains. Previous 95 
studies have revealed biofilm-forming ability of clinical isolates to be associated with C. albicans 96 
mortality (9). In addition, HBF isolates showed greater resistance to conventional antifungals, such 97 
as azoles and echinocandins (13). Interestingly, this study demonstrates that the effect of ACh on C. 98 
albicans metabolism is homogenous and independent of biofilm forming ability.  However, our 99 
recent data indicate that differences in amino acid metabolic pathways drives the biofilm phenotype 100 
(12), thus suggesting that the metabolic PM approach, which is based on reduction of tetrazolium 101 
salts, is unable to detect these differences. Nevertheless, in terms of drug discovery, our data 102 
indicates that C. albicans has the general ability to respond pharmacologically to this ubiquitous 103 
molecule, suggesting a conserved, yet unrecognised, ACh target. Given the uniform response then it 104 
is plausible that ACh and analogous molecules could be harnessed for therapeutic benefit.  105 
Although yeast growth has been modelled previously using PM analysis (6), to our knowledge this is 106 
the first report demonstrating the use of the technology to investigate the effects of 107 
pharmacological intervention on clinically relevant C. albicans isolates in real time. Therefore, it 108 
opens up the possibility of utilising PM technology for rapid high throughput screening of compound 109 
libraries for the development of novel anti-fungal drugs, as well as investigating the resistance to 110 
traditional antifungals in real time. This technology offers advantages over subjective endpoint CLSI 111 
based sensitivity testing and creates opportunities to supersede existing metabolic based screening 112 
tools, such as XTT, which are not without their limitations (10). Though the initial start-up expense 113 
for this approach is not inconsequential, it lends itself to high throughput automation. 114 
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Figure legends 115 
FIG 1: Diagrammatic representation of the parameters derived from the four parameter logistic fit of 116 
average metabolic measurements for each C. albicans isolate. Values such as the Mmin, Mmax, time to 117 
reach the inflection point (ti), t 0.5 and the gradient and area under the curve (AUC) can be 118 
determined directly from the charted metabolic data; whereas µ max was calculated from the 119 
equation and all were utilised to determine the metabolic activity curve characteristics for strain or 120 
drug treatments.   121 
 122 
FIG 2: Key differences in metabolic profiles between C. albicans bloodstream isolates grown in RPMI 123 
in the presence (grey bars) and absence (white bars) of 25 mg/ml acetylcholine. The results 124 
represent the mean and standard deviation of the lag time prior to the log phase of metabolic 125 
output (hours), the time (t 0.5) to reach 50% of the peak level of metabolic activity (hours) and the 126 
gradient of the log phase representing the exponential increase in C. albicans metabolic rate (Ln 127 
M/h). *** Significant difference (p<0.001) as assessed by a paired sample t-test with a Bonferroni 128 
correction between control and acetylcholine treated C. albicans. Data is derived from triplicate 129 
curves for each condition for 92 C. albicans bloodstream isolates.  130 
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